Efficacy of recombinant human soluble thrombomodulin in induction therapy for acute promyelocytic leukemia

Matsuda, Kensuke; Jo, Taisuke; Toyama, Kazuhiro; Nakazaki, Kumi; Matsui, Hiroki; Fushimi, Kiyohide; Yasunaga, Hideo

doi:10.1016/j.thromres.2021.04.003

Cited by 7 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42,56 However, novel results comparing APL patients anticoagulated with rTM and those without anticoagulants showed no improvement in in-hospital mortality and thrombotic events occurrence. 56 Due to rTM questionable effectiveness, its use is currently not proposed by guidelines. 23…”

Section: Management Of Thrombosis In Aplmentioning

confidence: 99%

“…42,56 Furthermore, rTM possesses anti-inflammatory effects which could be helpful in the setting of APL thromboinflammation-induced hypercoagulability. 42,56 However, novel results comparing APL patients anticoagulated with rTM and those without anticoagulants showed no improvement in in-hospital mortality and thrombotic events occurrence. 56 Due to rTM questionable effectiveness, its use is currently not proposed by guidelines.…”

Section: Management Of Thrombosis In Aplmentioning

confidence: 99%

See 1 more Smart Citation

Thrombosis in Acute Promyelocytic Leukemia: The Current Understanding

Sabljic,

Mitrovic,

Pantic

et al. 2024

Hamostaseologie

View full text Add to dashboard Cite

Despite enormous improvement in the management of patients with acute promyelocytic leukemia (APL), the distinctive coagulopathy observed at presentation in affected patients is often life-threatening. While hemorrhagic manifestations are well known and described in this setting, APL-related thromboses are underappreciated. Data regarding this complication are scarce showing variable incidence. Furthermore, risk factors for thrombosis are inconsistent and unreliable; so, differentiation of increased risk of hemorrhage from an increased thrombotic risk is quite difficult in the absence of adequate predictive scores. Besides, prophylactic use of anticoagulants and recombinant thrombomodulin are a matter of ongoing debate. Also, due to the common feature of thrombocytopenia and other hemorrhagic risks, patients with APL are excluded from trials analyzing anticoagulant prophylaxis in cancers; so, data from prospective trials are lacking. A detailed analysis of thrombotic risks in APL with the development of a reliable risk stratification model is needed to further improve the care of APL patients.

show abstract

Section: Management Of Thrombosis In Aplmentioning

confidence: 99%

Section: Management Of Thrombosis In Aplmentioning

confidence: 99%

Thrombosis in Acute Promyelocytic Leukemia: The Current Understanding

Sabljic,

Mitrovic,

Pantic

et al. 2024

Hamostaseologie

View full text Add to dashboard Cite

show abstract

“…In addition, because >70% of patients with APL were reported to develop coagulopathy [13], we further selected patients who required fresh frozen plasma (FFP) transfusion within 3 days of admission to more accurately identify APL patients from the database. This definition was also used in our previous studies [9,14]. Patient covariates included age, sex, body mass index (BMI), activities of daily living, Charlson comorbidity index (CCI) [15], initial FFP transfusion volume (i.e., initial transfusion volume of FFP per body weight within 3 days of admission), and emergency admission.…”

Section: Dear Editormentioning

confidence: 99%

Institutional factors associated with early mortality of newly diagnosed acute promyelocytic leukemia

Matsuda

Matsui

et al. 2022

Blood Cancer J.

Self Cite

View full text Add to dashboard Cite

“…TNF-α downregulates transcription of thrombomodulin, with an in vivo study demonstrating >80% (57,58). The use of rTM for patients with APL has become common in Japan, though a recent retrospective report did not find evidence of improved clinical outcomes (59).…”

Section: Mechanisms Of Thrombosis In Aplmentioning

confidence: 99%

“…Some centers have used recombinant factor VII for APL patients with an intracranial hemorrhage, but there is limited literature to support standard utilization in life-threatening hemorrhage at this time (80,81). The use of recombinant thrombomodulin has been reported and was well-tolerated, though small patient populations limit the ability to judge clinical effectiveness (57,59,82).…”

Section: Heparinmentioning

confidence: 99%

Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?

2021

View full text Add to dashboard Cite

Acute promyelocytic leukemia (APL) is characterized by frequent complications due to a distinct coagulopathy. While advances in treatments have improved long-term survival, hemorrhagic and thrombotic complications remain the most common causes of death and morbidity. Improved understanding of the mechanisms of the coagulopathy associated with APL may lead to therapeutic interventions to mitigate the risk of hemorrhage and thrombosis.

show abstract

Efficacy of recombinant human soluble thrombomodulin in induction therapy for acute promyelocytic leukemia

Cited by 7 publications

References 13 publications

Thrombosis in Acute Promyelocytic Leukemia: The Current Understanding

Thrombosis in Acute Promyelocytic Leukemia: The Current Understanding

Institutional factors associated with early mortality of newly diagnosed acute promyelocytic leukemia

Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?

Contact Info

Product

Resources

About